Patent: 10,005,847
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,005,847
Title: | Anti-HER2 glycoantibodies and uses thereof |
Abstract: | The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered. |
Inventor(s): | Wong; Chi-Huey (Rancho Santa Fe, CA), Wu; Chung-Yi (New Taipei, TW) |
Assignee: | ACADEMIA SINICA (Taipei, TW) |
Application Number: | 14/723,181 |
Patent Claims: | see list of patent claims |
Details for Patent 10,005,847
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2034-05-27 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2034-05-27 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2034-05-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |